Alivus Life Sciences share price
You have to be logged in to add this to Watchlist.- ₹923.30(0.32%)March 10, 2026 09:32:19 AM IST
- NSE
- BSE
- Vol : 3.04 K (NSE + BSE)Last 20 day avg : 61.13 K
Alivus Life Sciences is trading 0.32% upper at Rs 923.30 as compared to its last closing price. Alivus Life Sciences has been trading in the price range of 925.00 & 918.75. Alivus Life Sciences has given 0.34% in this year & 0.87% in the last 5 days. Alivus Life Sciences has TTM P/E ratio 20.62 as compared to the sector P/E of 23.53.There are 4 analysts who have initiated coverage on Alivus Life Sciences. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 150.26 Crores in its last quarter.Listed peers of Alivus Life Sciences include Cipla (0.06%), Sun Pharmaceutical Industries (0.93%), Divi's Laboratories (1.43%).The Mutual Fund holding in Alivus Life Sciences was at 5.44% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Alivus Life Sciences was at 5.08% in 31 Dec 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Mar 10, 2026, 04:16 AM UTC
- BetaMedium volatility1.11Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.02The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.55Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation5.88The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Cipla | Bearish | 1,326.00 | 0.06 | 1,07,529.62 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | Bullish | 1,824.50 | 0.93 | 4,37,748.35 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | Bullish | 6,427.50 | 1.43 | 1,70,200.19 | 78.61 | 11.52 | 0.46 | 0.01 |
| Torrent Pharmaceuticals | Bullish | 4,420.40 | 1.13 | 1,49,286.18 | 67.32 | 17.1 | 0.83 | 17.62 |
| Dr Reddy's Laboratories | Bullish | 1,313.25 | 2.09 | 1,09,852.02 | 18.63 | 3.14 | 0.63 | 2.34 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-01-22 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-08-01 | Quarterly Results |
| 2025-05-15 | Audited Results & Final Dividend |
| 2025-01-23 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE03Q201024
- BSE Code543322
- NSE CodeALIVUS
Alivus Life Sciences is trading at 923.30 as on Tue Mar 10 2026 04:02:19. This is 0.32% upper as compared to its previous closing price of 920.35.
The market capitalization of Alivus Life Sciences is 11342.11 Cr as on Tue Mar 10 2026 04:02:19.
The average broker rating on Alivus Life Sciences is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Alivus Life Sciences is 1224.00 whereas the 52 wk low is 827.10
Alivus Life Sciences can be analyzed on the following key metrics -
- TTM P/E: 20.62
- Sector P/E: 23.53
- Dividend Yield: 0.54%
- D/E ratio: -
Alivus Life Sciences reported a net profit of 485.63 Cr in 2025.
The Mutual Fund Shareholding was 5.44% at the end of 31 Dec 2025.